Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98–105. https://doi.org/10.1136/heartjnl-2018-313599

Article  PubMed  Google Scholar 

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912–4018. https://doi.org/10.1093/eurheartj/ehae178

Article  PubMed  Google Scholar 

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071. https://doi.org/10.1097/HJH.0000000000003480

Article  CAS  PubMed  Google Scholar 

Kario K, Kai H, Rakugi H, Hoshide S, Node K, Maekawa Y, et al. Consensus Statement on Renal Denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS). Circ J. 2024;88:1718–25. https://doi.org/10.1253/circj.CJ-66-0225

Article  PubMed  Google Scholar 

Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64:1012–21. https://doi.org/10.1161/HYPERTENSIONAHA.114.03850

Article  CAS  PubMed  Google Scholar 

Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183–6.

Article  CAS  PubMed  Google Scholar 

Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GDO, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–809. https://doi.org/10.1001/jama.294.14.1799

Article  Google Scholar 

Levent C. Fibrinogen and Atherosclerosis. Arquivos Brasileiros de Cardiologia. 2017;108:189–190. https://doi.org/10.5935/abc.20170017

Article  CAS  Google Scholar 

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20. https://doi.org/10.1056/NEJMoa1107477

Article  Google Scholar 

Shankar A, Wang JJ, Rochtchina E, Mitchell P. Positive association between plasma fibrinogen level and incident hypertension among men: population-based cohort study. Hypertension. 2006;48:1043–9. https://doi.org/10.1161/01.HYP.0000245700.13817.3c

Article  CAS  PubMed  Google Scholar 

Hermida-Ameijeiras A, Vazquez-Agra N, Cruces-Sande A, Mendez-Alvarez E, Soto-Otero R, Lopez-Paz J-E, et al. Implications of Inflammatory and Oxidative Stress Markers in the Attenuation of Nocturnal Blood Pressure Dipping. J Clin Med. 2023;12:1643. https://doi.org/10.3390/jcm12041643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Köktürk U, Püşüroğlu H, Çetin İ, Somuncu MU, Avcı A, Ertürk M. Prognostic impact of fibrinogen in patients with resistant hypertension. J Hum Hypertens. 2024. https://doi.org/10.1038/s41371-024-00964-9.

Sulimai N, Brown J, Lominadze D. Fibrinogen Interaction with Astrocyte ICAM-1 and PrPC Results in the Generation of ROS and Neuronal Death. Int J Mol Sci. 2021;22:2391. https://doi.org/10.3390/ijms22052391

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Bundy JD, Hamm LL, Hsu C-Y, Lash J, Miller ER, et al. Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease. Hypertension. 2019;73:785–93. https://doi.org/10.1161/HYPERTENSIONAHA.118.12358

Article  CAS  PubMed  Google Scholar 

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739–48. https://doi.org/10.1161/CIRCULATIONAHA.112.122556

Article  CAS  PubMed  Google Scholar 

Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82:279–85. https://doi.org/10.1016/j.jjcc.2023.05.006

Article  PubMed  Google Scholar